The finding, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, represents a disappointment to oncologists who had hoped to find distinct biomarkers beyond standard HER2 testing that could help them gauge how well Herceptin will work for patients.
"This study debunks the hopeful notion, strongly felt in the breast cancer community, that measuring levels of a number of different proteins in the HER2 family could help oncologists better tailor their use of Herceptin," says the study's senior investigator, Edith Perez, M.D., director of Mayo Clinic's Breast Program in Florida.
"Improving our ability to predict the benefit of Herceptin treatment beyond testing for HER2 protein and genes remains an important goal, but we are not there yet," she says.
Currently, patients are considered eligible for Herceptin if a pathologist estimates that at least 10 percent of their tumor samples test positive for HER2 growth proteins. However, the test is relatively subjective, based on a HER2 stain on a slide of tumor tissue. While the test can predict the outcome of Herceptin treatment, which shuts down the HER2 growth receptor for some patients, it cannot do so for all patients, Dr. Perez says.
Researchers used a tool that precisely measures the amount of a protein expressed in a cancer sample. According to Dr. Perez, this study was the first to meticulously measure protein levels, including HER2, HER3, HER4, EGFR (epidermal growth factor receptor), ER (estrogen receptor), and PTEN (a tumor suppressor gene) in almost 1,400 tumor biopsies.
Many researchers thought that analysis of the HER3 protein might be a good predictive marker because HER2 and HER3 interact together to promote cancer growth, Dr. Perez says.
"A biopsy could have 80 percent HER3 protein, and it wouldn't be any different in terms of a patient's outcome from Herceptin use than a tumor that had 5 percent HER3 protein," she says.
The next step to finding predictive biomarkers showing a benefit to Herceptin use will be to look at multi-gene profiles, not single biomarkers, Dr. Perez says.
The study was led by Dr. Perez and her team at Mayo Clinic with the collaboration of David Rimm, M.D., Ph.D., at Yale School of Medicine, and investigators who enrolled patients in the N9831 trial throughout the United States. The work was funded by the National Institutes of Health and the Breast Cancer Research Foundation. The original N9831 patient study was partially supported by the National Cancer Institute and Genentech.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. For more information, visit www.mayoclinic.org/about/ and www.mayoclinic.org/news.
Joe Dangor | EurekAlert!
Infants later diagnosed with autism follow adults’ gaze, but seldom initiate joint attention
24.05.2019 | Schwedischer Forschungsrat - The Swedish Research Council
When wheels and heads are spinning - DFG research project on motion sickness in automated driving
22.05.2019 | Technische Universität Berlin
A new assessment of NASA's record of global temperatures revealed that the agency's estimate of Earth's long-term temperature rise in recent decades is accurate to within less than a tenth of a degree Fahrenheit, providing confidence that past and future research is correctly capturing rising surface temperatures.
The most complete assessment ever of statistical uncertainty within the GISS Surface Temperature Analysis (GISTEMP) data product shows that the annual values...
Physicists at the University of Basel are able to show for the first time how a single electron looks in an artificial atom. A newly developed method enables them to show the probability of an electron being present in a space. This allows improved control of electron spins, which could serve as the smallest information unit in a future quantum computer. The experiments were published in Physical Review Letters and the related theory in Physical Review B.
The spin of an electron is a promising candidate for use as the smallest information unit (qubit) of a quantum computer. Controlling and switching this spin or...
Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...
With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.
Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...
'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.
However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...
29.04.2019 | Event News
17.04.2019 | Event News
15.04.2019 | Event News
24.05.2019 | Physics and Astronomy
24.05.2019 | Medical Engineering
24.05.2019 | Life Sciences